Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is set to present its latest research at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization (AAAAI/WAO) Joint Congress, which is taking place in San Diego from 28 February to 3 March.
The event brings together clinicians and researchers focused on allergy, asthma, and immunology.
The company will showcase findings from its Phase III trial of Grass MATA MPL, a short-course immunotherapy for grass pollen allergies, in one of six posters at the international gathering.
The study compares its effectiveness against two approved treatments. Another presentation will highlight the G308 Phase III trial, which began in November 2024, assessing the long-term safety and efficacy of Grass MATA MPL in children and adolescents.
Research on its peanut allergy vaccine, VLP Peanut, will also be presented. Interim results from the ongoing Phase I/IIa PROTECT trial, reported in December 2024, suggest a favourable safety profile.
The congress, hosted by the American Academy of Allergy, Asthma & Immunology and the World Allergy Organization, is a key platform for sharing scientific advancements in the field.
Allergy's CEO, Manuel Llobet, said: "We are delighted to be showcasing our leading research at this year's AAAAI / WAO Joint Congress, with six posters that highlight our commitment to transforming patients' lives through innovative therapies.
"Last year's submission of our marketing authorisation application for Grass MATA MPL, the initiation of our G308 Phase III trial in paediatric patients suffering from grass pollen allergy and the positive interim data from our ongoing VLP Peanut PROTECT trial, all illustrate the strength and pace of innovation at Allergy Therapeutics.
"We look forward to sharing more about our progress and learning from others at this important congress."